Core Viewpoint - The AI Fund Galaxy State-Owned Enterprise Theme Mixed Initiation A (019797) reported a profit of 192,400 yuan in Q2 2025, with a weighted average profit per fund share of 0.0192 yuan, and a net value growth rate of 1.87% during the reporting period [3][4]. Fund Performance - As of July 17, the fund's unit net value was 1.063 yuan, with a three-month net value growth rate of 3.82%, ranking 565 out of 615 comparable funds [4]. - The fund's six-month net value growth rate was 3.23%, ranking 534 out of 615, and the one-year growth rate was 5.06%, ranking 521 out of 584 [4]. - Since inception, the fund's Sharpe ratio is 0.4429 [9]. - The maximum drawdown since inception is 17.06%, with the largest quarterly drawdown occurring in Q4 2024 at 11.61% [12]. Fund Management Strategy - The fund manager, Zhu Jianhui, emphasizes adherence to the fund's style contract, focusing investments on state-owned listed companies, prioritizing dividend and low-volatility industry assets [3]. - The strategy includes identifying growth or innovative opportunities in specific sub-industries under economic pressure, particularly in new consumer sectors driven by domestic demand, export companies that can avoid tariffs, and innovative pharmaceutical and technology sectors [3]. Fund Holdings - As of Q2 2025, the fund's total assets amounted to 10.4612 million yuan [16]. - The top ten holdings include Agricultural Bank of China, China Merchants Bank, China International Capital Corporation, China Mobile, New Hope Liuhe, AVIC Optoelectronics, Tencent Holdings, Jiangsu Bank, CITIC Securities, and Industrial and Commercial Bank of China [19]. Investment Positioning - The average stock position since inception is 86.7%, compared to the industry average of 83.12%, with a peak stock position of 91.85% at the end of H1 2025 and a low of 81.91% at the end of H1 2024 [15].

长城医药科技六个月持有期混合型证券投 资基金 基金管理人：长城基金管理有限公司 基金托管人：中国农业银行股份有限公司 报告送出日期：2025 年 7 月 12 日 长城医药科技六个月混合 2025 年第 2 季度报告 §1 重要提示 本基金管理人的董事会及董事保证本报告所载资料不存在虚假记载、误导性陈述或重大遗漏， 并对其内容的真实性、准确性和完整性承担个别及连带责任。 本基金托管人中国农业银行股份有限公司根据本基金合同规定，于 2025 年 07 月 11 日复核了 本报告中的财务指标、净值表现和投资组合报告等内容，保证复核内容不存在虚假记载、误导性 陈述或者重大遗漏。 本基金管理人承诺以诚实信用、勤勉尽责的原则管理和运用基金资产，但不保证基金一定盈 利。 基金的过往业绩并不代表其未来表现。投资有风险，投资者在作出投资决策前应仔细阅读本 基金的招募说明书。 本报告中财务资料未经审计。 本报告期自 2025 年 04 月 01 日起至 2025 年 06 月 30 日止。 §2 基金产品概况 基金简称 长城医药科技六个月混合 基金主代码 011673 基金运作方式 契约型开放式 基金合同生效日 2021 年 ...